Impact of maternal obesity on very preterm infants

Rubia Khalak1, Asha Rijhsinghani2, Sarah E McCallum3

  • 1Department of Pediatrics/Neonatology Division, Albany Medical Center, Albany, New York, USA.

Insights

Maternal obesity, particularly level III obesity, increases the need for delivery room resuscitation in very preterm infants. This finding highlights potential impacts on intensive care resource utilization for these vulnerable newborns.

Area of Science:

  • Neonatalogy
  • Maternal-Fetal Medicine
  • Public Health

Background:

  • Infants born before 34 weeks' gestation face heightened risks of morbidity and mortality.
  • Limited data exist on how maternal obesity affects very preterm infants' intensive care requirements.

Purpose of the Study:

  • To investigate if maternal obesity exacerbates the intensive care needs of infants born before 34 weeks' gestational age.

Main Methods:

  • Retrospective review of maternal and neonatal data for singleton births between 23 0/7 and 33 6/7 weeks' gestation.
  • Maternal Body Mass Index (BMI) categorized using NIH classifications, including three ascending obesity levels.

Main Results:

  • 31.6% of 1,224 women studied had obesity.
  • Infants born to mothers with level III obesity showed significantly higher rates of delivery room (DR) resuscitation (63.2%, P=0.04).
  • A trend indicated a continued need for assisted ventilation beyond 6 hours for infants of mothers with level III obesity (54.7%, P=0.06).

Conclusions:

  • Very preterm infants born to mothers with level III obesity are more likely to require DR resuscitation.
  • There is a trend suggesting these infants may need ongoing ventilatory support, impacting DR resource allocation.
Abstract

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
4.0K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.2K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
320
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
259
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.4K